Durvalumab

Catalog No.A2013 Synonyms: MEDI4736 Non-humanized mouse model applicable

For research use only. Not for use in humans.

Durvalumab is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.

Size Price Stock Quantity  
USD 707 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Quality Control

Choose Selective PD-1/PD-L1 Inhibitors

Biological Activity

Description Durvalumab is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.
Targets
PD-L1/CD80 [1]
(HTRF assay)
PD-1/PD-L1 interaction [1]
(HTRF assay)
0.04 nM 0.1 nM
In vitro

MEDI4736 is a potent antagonist of PD-L1 function, blocking interaction with PD-1 and CD80 to overcome inhibition of primary human T-cell activation. It does not trigger antibody-dependent cellular cytotoxicity (ADCC)[2].

In vivo In vivo MEDI4736 significantly inhibits the growth of human tumors in a novel xenograft model containing coimplanted human T cells[2]. In patients with advanced solid tumors, The linear clearance, volume of distribution and concentration at half maximal elimination (KM) of MEDI4736 are 240 mL/day, 3.6 L and 0.4 μg/mL, respectively. The half-life is ~23 days at doses ≥ 3 mg/kg Q2W. Greater than 99% target saturation (soluble and membrane bound) is expected at ≥40 μg/mL of MEDI4736[3].

Protocol

Product Details

Formulation PBS buffer, pH 7.2
Isotype Human IgG1
Source CHO cells
Storage Store at -80°C and avoid freeze-thaw cycles.

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03519971 Recruiting Non-Small Cell Lung Cancer AstraZeneca April 9 2018 Phase 3
NCT03405454 Recruiting Ovarian Clear Cell Carcinoma National University Hospital Singapore October 9 2017 Phase 2
NCT02369874 Active not recruiting Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN AstraZeneca September 9 2015 Phase 3
NCT02273375 Recruiting Non-Small Cell Lung Cancer Canadian Cancer Trials Group|Intergroupe Francophone de Cancerologie Thoracique (IFCT)|Australasian Lung Cancer Trials Group|National Health and Medical Research Council Australia|National Cancer Institute (NCI) Naples|Central and Eastern European Oncology Group|Dutch Society of Physicians for Pulmonology and Tuberculosis|Korean Cancer Study Group|Spanish Lung Cancer Group|West Japan Oncology Group (WJOG)|Chinese Thoracic Oncology Group October 9 2014 Phase 3
NCT03376659 Recruiting Metastatic Colorectal Cancer|Colorectal Adenocarcinoma|Pancreatic Adenocarcinoma|Metastatic Pancreatic Cancer Georgetown University|Mayo Clinic|Indiana University|Emory University|National Cancer Institute (NCI)|George Mason University|Thomas Jefferson University|MedImmune LLC|Bavarian Nordic Inc. August 8 2018 Phase 1|Phase 2
NCT03011814 Recruiting Folliculotropic Mycosis Fungoides|Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides|Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Peripheral T-Cell Lymphoma Not Otherwise Specified|Sezary Syndrome|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma City of Hope Medical Center|National Cancer Institute (NCI) March 8 2017 Phase 1|Phase 2

Tech Support

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
Tags: buy Durvalumab | Durvalumab supplier | purchase Durvalumab | Durvalumab cost | Durvalumab manufacturer | order Durvalumab | Durvalumab distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID